Acceleron Pharma (XLRN) Misses Q4 EPS Expectations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Misses Q4 EPS Expectations

Acceleron Pharma Reports Fourth Quarter and Year Ended 2015 Financial and Operational Results and Recent Highlights

February 25, 2016 7:00 AM EST

- Initiated Phase 3 trials with luspatercept in MDS and beta-thalassemia with partner Celgene -

- Received Fast Track Designation for luspatercept in MDS and beta-thalassemia, and for dalantercept in RCC -

- Presented initial Phase 1 results for ACE-083, a locally acting therapeutic candidate for muscle diseases -

- Introduced ACE-2494, Acceleron's first IntelliTrap molecule, a therapeutic candidate for systemic muscle diseases -

- Raised $150 million in gross proceeds to advance wholly owned programs, including locally acting and systemic agents for muscle diseases... More